---
title: "Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293788160.md"
description: "Taysha Gene Therapies highlighted its TSHA-102 gene therapy for Rett syndrome, outlining a registration strategy. The REVEAL pivotal trial completed dosing in 17 patients, with Part A data showing a 100% response rate and no serious adverse events. A 6-month interim readout is targeted for the first half of 2027. Taysha cites FDA alignment for a potential BLA submission based on this analysis. Additionally, the ASPIRE trial remains ongoing to support a broader label."
datetime: "2026-07-24T18:46:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293788160.md)
  - [en](https://longbridge.com/en/news/293788160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293788160.md)
---

# Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome

-   Taysha outlined a registration strategy for TSHA-102, a one-time intrathecal AAV9 gene therapy candidate for Rett syndrome. \* REVEAL pivotal trial dosing completed in 17 females ages 6 to <22 years at 1x10^15 total vg; 6-month interim readout targeted for 1H 2027. \* REVEAL Part A data showed a 100% response rate on the primary endpoint in 12 patients; no treatment-related serious adverse events or dose-limiting toxicities reported. \* FDA alignment cited for a potential BLA submission based on the pivotal trial 6-month interim analysis, with Part A data included for comparability. \* ASPIRE trial in 4 females ages 2 to years remained ongoing; dosing completion expected in July 2026 to support a broad label for patients age 2+. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support](https://longbridge.com/en/news/294689795.md)
- [Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation](https://longbridge.com/en/news/291157030.md)
- [Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million](https://longbridge.com/en/news/294812276.md)
- [Ocugen Q2 revenue beats estimates](https://longbridge.com/en/news/295098725.md)
- [Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients](https://longbridge.com/en/news/295104705.md)